「Targeted epigenetic induction of mitochondrial biogenesis enhances antitumor immunity in mouse model」の関連論文
-
Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer
-
Finding potential synergistic drugs to reduce chemo-resistance for the treatment of highly malignant tumors in female
-
Study of the Effects of Inhibition of Epigenetic Regulators on the Proliferation of Hematological Malignant Tumor Cells
-
Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer
-
Reduced Number and Immune Dysfunction of CD4+ T Cells in Obesity Accelerate Colorectal Cancer Progression
-
A Review of T-Cell Related Therapy for Osteosarcoma
-
The mutual relationship between the host immune system and radiotherapy: stimulating the action of immune cells by irradiation
-
Hernandezine induces multiple cancer cell death
-
JNK and Yorkie drive tumor malignancy by inducing L-amino acid transporter 1 in Drosophila
-
Project 1 Analyzing Tumor Microenvironment and Exploiting its Characteristics in Search of Optimizing Cancer Therapy Including Neutron Capture Therapy (R2P1)
-
Preclinical evaluation of the efficacy of an antibody to human SIRPα for cancer immunotherapy in humanized mouse models
-
Constitutively active signaling of MDA5 in Treg cells causes apoptosis of Treg cells and results in autoimmune diseases
-
Generation of GM-CSF-producing antigen-presenting cells that induce a cytotoxic T cell-mediated antitumor response
-
Impaired CD4⁺ T cell response in older adults is associated with reduced immunogenicity and reactogenicity of mRNA COVID-19 vaccination
-
Retinoic acid receptor activity is required for the maintenance of type 1 innate lymphoid cells
-
The ATR inhibitor AZD6738 increases the sensitivity of 5-fluorouracil in colorectal cancer cells by abrogating repair of DNA damage
-
Interleukin (IL)-17A is a potent prognostic factor associated with intratumoral neutrophil infiltration and C-X-C chemokine motif ligand 1 in triple-negative breast cancer
-
Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells
-
Randomized Phase II Study of Gemcitabine Monotherapy vs. Gemcitabine with an EPAEnriched Oral Supplement in Advanced Pancreatic Cancer
-
Anti-diabetic drug metformin inhibits cell proliferation and tumor growth in gallbladder cancer via G0/G1 cell cycle arrest
-
T cell receptor-engineered T cells derived from target human leukocyte antigen-DPB1-specific T cell can be a potential tool for therapy against leukemia relapse following allogeneic hematopoietic cell transplantation
-
In vivo induction of activin A-producing alveolar macrophages supports the progression of lung cell carcinoma
-
The ratio of CD8 + lymphocytes to tumor-infiltrating suppressive FOXP3 + effector regulatory T cells is associated with treatment response in invasive breast cancer
-
Development of a novel cancer therapy with a ferroptosis inducer and radiation, and a prediction method for therapeutic effects targeting ferroptosis
-
T-cell response to phytohemagglutinin in the interferon-γ release assay as a potential biomarker for the response to immune checkpoint inhibitors in patients with non-small cell lung cancer
-
The Interaction between Cancer-associated Fibroblasts and Cancer Cells Enhances Bcl-xL and Mcl-1 in Colorectal Cancer
-
Gold Nanoparticles Enhance the Tumor Growth-Suppressing Effects of Cetuximab and Radiotherapy in Head and Neck Cancer In Vitro and In Vivo
-
Efficacy of the Novel Tubulin Polymerization Inhibitor PTC-028 for Myelodysplastic Syndrome
-
Chemosensitivity of Patient-Derived Cancer Stem Cells Identifies Colorectal Cancer Patients with Potential Benefit from FGFR Inhibitor Therapy
-
A novel cancer immunotherapy using tumor-infiltrating B cells in the APC (min/+) mouse model
-
Neutrophil Extracellular Traps Promote Metastases of Colorectal Cancers through Activation of ERK Signaling by Releasing Neutrophil Elastase
-
Metformin Inhibits Proliferation and Tumor Growth of QGP-1 Pancreatic Neuroendocrine Tumor Cells by Inducing Cell Cycle Arrest and Apoptosis
-
TLR-MyD88-signaling blockades inhibit refractory B-1b cell immune responses to transplant-related glycan antigens
-
TLR-MyD88-signaling blockades inhibit refractory B-1b cell immune responses to transplant-related glycan antigens
-
A recombinant adenovirus vector containing the synNotch receptor gene for the treatment of triple-negative breast cancer
-
GSK3 inhibitor enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells by overcoming multiple mechanisms of resistance
-
Clinical significance of BIM deletion polymorphism on chemoradiotherapy in patients with non-small cell lung cancer.
-
Clinical significance of BIM deletion polymorphism on chemoradiotherapy in patients with non-small cell lung cancer.
-
Enhancement of antitumor immune response by radiation therapy combined with dual immune checkpoint inhibitor in a metastatic model of HER2-positive murine tumor
-
Profiling of Naquotinib, a Small Molecule Kinase Inhibitor, as EGFR and BTK Inhibitor
-
Characterization of cisplatin effects in lenvatinib‐resistant hepatocellular carcinoma cells
-
Studies on Cytotoxic Effects of Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) to Canine Cell Lines Derived from Hemangiosarcoma and Mammary Epithelial Tumor
-
Design of Novel Targeted Co-delivery System for Combined Chemotherapy and Gene Therapy of Hepatocellular Carcinoma [an abstract of entire text]
-
Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation pathway mediated by opioid receptor kappa 1
-
Enhanced G1 arrest and apoptosis via MDM4/MDM2 double knockdown and MEK inhibition in wild-type TP53 colon and gastric cancer cells with aberrant KRAS signaling
-
Inhibition of heat shock protein 90 destabilizes receptor tyrosine kinase ROR1 in lung adenocarcinoma
-
Molecular basis for ANGPTL2 recognition of LILRB2 immune checkpoint receptor [an abstract of entire text]
-
Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer
-
Immune checkpoint inhibitors for patients with pre-existing autoimmune diseases
-
Targeting tumor-intrinsic Nuclear Factor-kappa B signaling pathway for the discovery of anti-metastatic drug candidates from natural recourses